Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from EQS Group

11:13 EDT 18th September 2018 | BioPortfolio

Here are the most relevant search results for "EQS Group" found in our extensive news archives from over 250 global news sources.

More Information about EQS Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about EQS Group for you to read. Along with our medical data and news we also list EQS Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of EQS Group Companies for you to search.

Showing News Articles 1–25 of 794 from EQS Group

Tuesday 18th September 2018

STADA Arzneimittel AG: Voting results of the bondholders' meeting concerning the STADA-Bond 2015/2022

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond 18.09.2018 / 15:07 The issuer is solely responsible for the content of this announcement. Bad Vilbel, 18 September 2018 - STADA Arzneimittel Aktiengesellschaft ("STADA" or the "Issuer") today informed about the voting results of the meeting on 18 September 2018 (the "Bondholders' Meeting") of the bondholders (the "Bondholders") of the...

B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG announces strategic research collaboration with BluCon Biotech GmbH

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Strategic Company Decision 18.09.2018 / 08:59 The issuer is solely responsible for the content of this announcement. Chemicals from Renewable Resources BRAIN AG announces strategic research collaboration with BluCon Biotech GmbH Joint R&D work aims at microbial strain development for the produc...

Monday 17th September 2018

MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Alliance 17.09.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Martinsried/Munich, Germany, and Ballerup, Denmark, September 17, 2018   MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics   LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG...

EVOTEC AND ALMIRALL ENTER INTO RESEARCH COLLABORATION IN THE FIELD OF DERMATOLOGICAL DISEASES

DGAP-News: Evotec AG / Key word(s): Miscellaneous 17.09.2018 / 07:29 The issuer is solely responsible for the content of this announcement. EVOTEC AND ALMIRALL ENTER INTO RESEARCH COLLABORATION IN THE FIELD OF DERMATOLOGICAL DISEASES   - COLLABORATION IS FOCUSED ON FIRST-IN-CLASS THERAPIES TO TREAT DERMATOLOGICAL DISEASES - COLLABORATION LEVERAGES A NOVEL APPROACH TO DISRUPT CELL...

Friday 14th September 2018

RHÖN-KLINIKUM AG: Marburg Ion Beam Therapy operating firm of Heidelberg University Hospital mbH files insolvency petition

DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Miscellaneous/Miscellaneous 14.09.2018 / 13:30 The issuer is solely responsible for the content of this announcement. Bad Neustadt a. d. Saale | September 14th, 2018 Corporate News Marburg Ion Beam Therapy operating firm of Heidelberg University Hospital mbH files insolvency petition   The Management of Marburg Ion Beam Therapy opera...

UMS United Medical Systems International AG: UMS AG reports on the first three months of fiscal year 2018 / 19

DGAP-News: UMS United Medical Systems International AG / Key word(s): Quarterly / Interim Statement/Quarter Results 14.09.2018 / 10:00 The issuer is solely responsible for the content of this announcement. UMS AG reports on the first three months of fiscal year 2018 / 19 Hamburg, September 14, 2018. UMS United Medical Systems International AG i. L. (UMS, ISIN DE 0005493654 / WKN 549365...

Hardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations

Hardman & Co Research 14-Sep-2018 / 07:15 GMT/BST Hardman & Co: Strategy delivering growth above expectations TRX has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. The company has two proprietary decellularisation technology platforms, for the repair of tissues and bone. 2017 was a dynamic year for the group, growth ...

AEVIS VICTORIA SA: Growth and optimisation strategy continued in first semester 2018 while results were affected by one-off factors

AEVIS VICTORIA SA / Key word(s): Half Year Results 14-Sep-2018 / 07:10 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Press release Fribourg, 14 September 2018 AEVIS VICTORIA - Growth and optimisation strategy continued in first semester 2018 while results were affected by one-off factors AEVIS...

Thursday 13th September 2018

MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106 (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 13.09.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, and Mechelen, Belgium, September 13, 2018   MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106   MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Galap...

Correction of a release from 30.05.2018, 18:00 CET/CEST - Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG 13.09.2018 / 11:57 Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Correction of a publication dated 30.05.2018 1. Details of issuer Heidelberg Pharma AG Schriesheimer Str. 101 68526 Ladenburg Germany 2. Type of capital measure &n...

Correction of a release from 30.04.2018, 10:46 CET/CEST - Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG 13.09.2018 / 11:51 Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Correction of a publication dated 30.04.2018 1. Details of issuer Heidelberg Pharma AG Schriesheimer Str. 101 68526 Ladenburg Germany 2. Type of capital measure &n...

MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study results/Conference 13.09.2018 / 10:16 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, September 13, 2018 MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis MorphoSys AG (FS...

Formycon AG: Formycon Reports Financial and Operating Results for the First Half Year of 2018

DGAP-News: Formycon AG / Key word(s): Half Year Results/Research Update 13.09.2018 / 08:00 The issuer is solely responsible for the content of this announcement. Press Release // September 13, 2018 Formycon Reports Financial and Operating Results for the First Half Year of 2018 - Last patient completed treatment in COLUMBUS-AMD phase III study as scheduled in June - Turnover increase...

Wednesday 12th September 2018

MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Alliance 12.09.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany and Mechelen, Belgien, September 12, 2018   MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner   MorphoSys AG (FSE: MOR; Prime Standard Segment, Te...

M1 Kliniken AG: M1 Kliniken AG successfully completes capital increase.

M1 Kliniken AG / Key word(s): Corporate Action/Capital Increase M1 Kliniken AG: M1 Kliniken AG successfully completes capital increase. 12-Sep-2018 / 18:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. M1 Klin...

PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES

DGAP-News: PAION AG / Key word(s): Conference 12.09.2018 / 14:00 The issuer is solely responsible for the content of this announcement. PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES Aachen (Germany), 12 September 2018 - The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces its participation in four upcoming co...

STADA Arzneimittel AG: STADA invites the holders of the STADA Bond to participate in the bondholders' meeting and to vote in favor of the proposed resolutions

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond 12.09.2018 / 11:41 The issuer is solely responsible for the content of this announcement. Bad Vilbel, 12 September 2018 - On 24 August 2018, STADA Arzneimittel Aktiengesellschaft ("STADA" or the "Company") has invited the holders of its EUR 300,000,000 1.750% fixed-rate bearer notes 2015/2022 with ISIN: XS1213831362, WKN: A14KJP (the ...

Dermapharm Holding SE publishes report for first half of 2018

DGAP-News: Dermapharm Holding SE / Key word(s): Half Year Results 12.09.2018 / 07:30 The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE publishes report for first half of 2018 Group revenues increased by 19.7% to EUR 280.3 million Adjusted EBITDA rose by 29.9% to EUR 70.9 million; EBITDA margin improved to 25.3% New growth opportunitie...

4SC AG: 6 upcoming conferences and roadshows

DGAP-News: 4SC AG / Key word(s): Conference 12.09.2018 / 07:30 The issuer is solely responsible for the content of this announcement. 4SC AG: 6 upcoming conferences and roadshows Planegg-Martinsried, Germany, 12 September 2018 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation at upcoming conferences and roadshows. 4SC's management and scientists will be availabl...

Tuesday 11th September 2018

Expedeon AG announces commercial-use licence of proprietary technology in diagnostic assay (news with additional features)

DGAP-News: Expedeon AG / Key word(s): Agreement 11.09.2018 / 07:30 The issuer is solely responsible for the content of this announcement. PRESS RELEASE 11 September 2018 / Expedeon AG announces commercial-use licence of proprietary technology in diagnostic assay Heidelberg, Germany and Cambridge, UK, 11 September 2018 - Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard)...

Monday 10th September 2018

M1 Kliniken AG: M1 Kliniken AG decides to implement a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments

M1 Kliniken AG / Key word(s): Corporate Action/Capital Increase M1 Kliniken AG: M1 Kliniken AG decides to implement a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments 10-Sep-2018 / 18:23 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regu...

DGAP-DD: Epigenomics AG english

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 10.09.2018 / 11:47 The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated a) Name Name and legal form: Armin ...

Friday 7th September 2018

Edison Investment Research Limited: Edison issues initiation on Acacia Pharma (ACPH)

Edison Investment Research Limited 07-Sep-2018 / 10:41 GMT/BST London, UK, 7 September 2018 Edison issues initiation on Acacia Pharma (ACPH) Acacia Pharma is focused on bringing antiemetic drugs to the US hospital setting for unmet needs in post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). We expect FDA approval of Acacia's lead product, BARH...

AEVIS VICTORIA SA: artnership with Siloah AG, Gümligen and entry into the Bernese hospital market

AEVIS VICTORIA SA / Key word(s): Acquisition 07-Sep-2018 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Press release Fribourg, 7 September 2018 AEVIS VICTORIA SA: Partnership with Siloah AG, Gümligen and entry into the Bernese hospital market AEVIS VICTORIA SA (AEVIS VICTORIA), through...

Thursday 6th September 2018

Gerresheimer AG: Dietmar Siemssen appointed new CEO of Gerresheimer AG

DGAP-News: Gerresheimer AG / Key word(s): Change of Personnel 06.09.2018 / 11:46 The issuer is solely responsible for the content of this announcement. Dietmar Siemssen appointed new CEO of Gerresheimer AG - Dietmar Siemssen to assume as Chief Executive Officer on November 1, 2018 - Previously held position as Stabilus CEO - Speaker of the Management Board and CFO Rainer Beaujean wil...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks